Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Solid Tumors 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Colorectal Neoplasms 1

Interventions

Capecitabine 35Oxaliplatin 32Fluorouracil 29Leucovorin 26Irinotecan 22Bevacizumab 19Cetuximab 17Radiotherapy 16Radiation 11Surgical Procedures, Operative 6Radiotherapy, Intensity-Modulated 5Gene Expression Profiling 5Chemotherapy, Adjuvant 5Celecoxib 5Neoadjuvant Therapy 4Immunohistochemistry 4Biopsy 4Amplified Fragment Length Polymorphism Analysis 4cediranib 3Reverse Transcriptase Polymerase Chain Reaction 3Receptor Protein-Tyrosine Kinases 3Folfox protocol 3Drug Therapy 3Cisplatin 3sargramostim 2regorafenib 2pembrolizumab 2fludarabine phosphate 2aldesleukin 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Rectal Neoplasms × IT-101 × Clear all
NCT02010567 2020-11-03

Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Terminated
32 enrolled 18 charts
Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡